GALT (Galectin Therapeutics Inc.) Wutah bathi EPS kuartalan

Galectin Therapeutics (GALT) is systematically deploying liquid assets toward clinical trials, as evidenced by the quarterly EPS trend; an analysis on GURU.Markets reveals that -16.30 describes the current status of this metric. The business foundation is the innovative Belapectin designed to combat liver cirrhosis. Successful registration of the drug will grant the company monopoly pricing power within this niche.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan galectintherapeutics.com (GALT): kanggo periode 04.07.2022 - 15.11.2026

GALT (Galectin Therapeutics Inc.): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham Galectin Therapeutics, Inc.|GALT - Bagan rega target

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Galectin|GALT - Total Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham Galectin Therapeutics|GALT - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku galectintherapeutics.com|GALT - Aset Neraca Perusahaan

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal Galectin Therapeutics|GALT - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Galectin Therapeutics, Inc.|GALT - Utang perusahaan|Utang-utang marang kapitalisasi buku Galectin|GALT - Utang jangka dawa|Utang jangka cendhak perusahaan Galectin Therapeutics|Indikator likuiditas cepet galectintherapeutics.com

- rincian bathi lan kelipatan pasar:

GALT - Bathi sawise mbayar pajeg|Proyeksi bathi mangsa ngarep Galectin Therapeutics|GALT - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Galectin Therapeutics|GALT - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Galectin Therapeutics Inc.|GALT - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Galectin Therapeutics|GALT - Bathi saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan galectintherapeutics.com|GALT - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Galectin Therapeutics

- indikator pendapatan dodolan lan penghasilan bisnis:

GALT - Total pendapatan perusahaan|Prakiraan pendapatan perusahaan Galectin|GALT - Rasio kapitalisasi pasar marang pendapatan|Multiplikator Forward P/S Galectin Therapeutics Inc.

Pambiji fundamental:Galectin Therapeutics, Inc. - GALT

Barang unggulan galectintherapeutics.com

Galectin Therapeutics (GALT) focuses on developing a unique drug for the treatment of NASH with the potential for monopoly pricing power. This indicator measures the percentage change in net earnings per share compared to the same quarter of the previous year. Analyzing relative quarterly EPS dynamics allows for the identification of R&D cost management efficiency. An upward trend in the curve signals a transition toward scalable profits. The stability of this metric determines long-term investor confidence in the company's capital.

Analisis perusahaan pesaing